DrugTheGuide
Pharmacodynamics

Pharmacodynamic Tolerance

A reduction in drug response following repeated or continuous exposure — despite unchanged plasma concentrations — arising from receptor desensitisation, downregulation, mediator depletion, or compensatory pathway activation at the drug target. Distinct from pharmacokinetic pseudo-tolerance (enzyme induction reducing drug levels).

Definition and Classification

Pharmacodynamic (PD) tolerance occurs when the response to a drug decreases with repeated administration at the same plasma concentration — i.e., the concentration–effect relationship shifts rightward (EC50 increases, or Emax decreases). It is an intrinsic cellular adaptation at the level of the receptor or downstream signalling pathway.

It contrasts with pharmacokinetic (pseudo-)tolerance, where apparent tolerance results from reduced drug concentrations due to autoinduction of metabolic enzymes (e.g., carbamazepine inducing its own CYP3A4 metabolism). See our enzyme induction glossary.

Tachyphylaxis

Rapid onset tolerance developing within minutes to hours. Classic: beta-2 agonist receptor internalisation with continuous nebulisation; GTN patch tolerance within 24 hours.

Slow tolerance

Develops over days to weeks with chronic dosing. Examples: opioid analgesic tolerance (mu-receptor desensitisation/downregulation + AC superactivation); benzodiazepine hypnotic tolerance (GABA-A receptor desensitisation).

Molecular Mechanisms

  • Receptor phosphorylation/desensitisation: Chronic agonist stimulation activates GRK (G protein-coupled receptor kinase) or second-messenger kinases (PKA, PKC) → receptor phosphorylation → β-arrestin recruitment → uncoupling from G protein (signalling blocked) → receptor internalisation (sequestration in endosomes). Example: mu-opioid receptor (OPRM1) desensitisation by GRK2/3.
  • Receptor downregulation: Prolonged agonist exposure reduces total receptor expression — increased internalisation + lysosomal degradation, reduced de novo receptor synthesis (transcriptional repression). Long-term opioid, beta-2 agonist, and nicotinic receptor use.
  • Adenylyl cyclase (AC) superactivation: Chronic opioid-mediated Gi inhibition of AC leads to compensatory upregulation of AC isoforms. On opioid withdrawal, AC superactivation produces a cAMP surge → sympathetic hyperactivity, withdrawal syndrome. This is also the cellular correlate of opioid dependence.
  • Mediator depletion: Indirect-acting sympathomimetics (e.g., ephedrine, tyramine) displace norepinephrine from vesicles. Repeated dosing depletes the neurotransmitter pool → progressive reduction in pressor response.
  • Nitrate tolerance (soluble GC mechanism): Organic nitrates are bioactivated by mitochondrial aldehyde dehydrogenase (ALDH2) to nitric oxide → activates soluble guanylate cyclase (sGC) → ↑ cGMP → vasorelaxation. Tolerance involves superoxide generation (from uncoupled eNOS and xanthine oxidase) → inactivation of sGC and depletion of reduced glutathione. Managed by nitrate-free intervals (8–12 h/day for patches).

Clinical Management of Tolerance

  • Nitrate-free intervals: Remove GTN patches for 8–12h daily (overnight) to allow receptor/enzyme recovery. Wears off with short-acting nitrates at night.
  • ICS with LABA: Inhaled corticosteroids upregulate beta-2 receptor expression and prevent GRK-mediated downregulation — explaining why LABA monotherapy worsens asthma outcomes but ICS/LABA combination does not. See our respiratory pharmacology guide.
  • Opioid rotation: Switching opioids exploits incomplete cross-tolerance between mu-receptor subtypes — a different opioid may produce better analgesia at equivalent/lower dose. Used in cancer pain management.
  • Benzodiazepine tolerance: Dose escalation required for same hypnotic effect; stopping produces GABA-A upregulation and severe withdrawal (seizures at high doses). Managed by gradual taper using a long-acting agent (diazepam). See our psychiatric medication guide.

Reference: Bhargava 2006 — pharmacodynamic tolerance mechanisms (PubMed) ↗.

FAQ

What is pharmacodynamic tolerance?
Pharmacodynamic tolerance is a reduction in drug response following repeated or continuous exposure, despite unchanged plasma concentrations. It arises from adaptive changes at or downstream of the drug target — receptor desensitisation, receptor downregulation, depletion of mediators, or compensatory activation of opposing pathways. It is distinct from pharmacokinetic tolerance (pseudo-tolerance), where reduced response is explained by lower drug concentrations due to autoinduction of metabolism.
What is tachyphylaxis and how does it differ from tolerance?
Tachyphylaxis is a rapid, acute diminution of response following closely spaced or continuous drug exposure — developing over minutes to hours rather than days. It is a subtype of pharmacodynamic tolerance. The classic example is beta-2 agonist (salbutamol) tachyphylaxis with continuous nebulisation: prolonged beta-2 receptor stimulation triggers receptor phosphorylation by GRK2 (G protein-coupled receptor kinase 2), uncoupling the receptor from Gs protein and internalising it (internalisation/sequestration). The distinction from slower tolerance is quantitative rather than mechanistic — tachyphylaxis = rapid onset tolerance.
What are the mechanisms of pharmacodynamic tolerance?
Five main mechanisms: (1) Receptor desensitisation: phosphorylation of the receptor by second-messenger kinases (PKA, PKC) or GRKs uncouples it from its signalling effector without changing receptor density. (2) Receptor downregulation: chronic agonist exposure reduces the total number of receptors expressed at the cell surface (decreased gene transcription + increased internalisation/lysosomal degradation). (3) Mediator depletion: drugs that cause release of an endogenous mediator deplete it over time — e.g., ephedrine depletes norepinephrine from nerve terminals. (4) Compensatory physiological adaptation: counteracting regulatory systems oppose the drug effect — e.g., opioids upregulate adenylyl cyclase (AC superactivation) which opposes opioid inhibition of cAMP. (5) Tolerance at the signal transduction level: e.g., nitrate tolerance involves superoxide-mediated destruction of soluble guanylate cyclase cofactors.
What are clinical examples of pharmacodynamic tolerance?
Nitrate tolerance: continuous or frequent organic nitrate administration (GTN patches, isosorbide dinitrate) causes rapid tolerance within 24 hours — managed by nitrate-free intervals (8-12h daily patch-free period). Opioid tolerance: chronic opioid use requires dose escalation to maintain analgesia — involves mu-receptor desensitisation, downregulation, and AC superactivation. Beta-2 agonist tachyphylaxis: prolonged salbutamol exposure reduces bronchodilatory response — regular LABA use in asthma without ICS (ICS prevents receptor downregulation). Benzodiazepine tolerance: GABA-A receptor desensitisation over days to weeks; pharmacodynamic tolerance underlies both reduced hypnotic efficacy and physiological dependence. Antihypertensive tolerance: loop diuretics lose effectiveness with chronic use due to distal tubular hypertrophy compensating sodium reabsorption.